In July, FDA approved nirsevimab-alip (Beyfortus—Sanofi/AstraZeneca). A few weeks later, on August 3, 2023, CDC’s ACIP voted unanimously to recommend the broad use of the new drug to infants and high-risk children for protection against respiratory syncytial virus (RSV).

A new study published in NEJM found that cholesterol-lowering statin drugs helped curb the risk of significant CVD in people living with HIV by more than one-third, potentially preventing one in five major CV events or premature deaths in this population.